IDG Capital et al. back $67m series-C for Hifibio

IDG Capital led the round, with Delian Capital, Hanne Capital and Kite (part of the biopharmaceutical company Gilead), backing the business for the first time. Existing investors Sequoia Capital China, VI Ventures, Legend Star Capital and Lyfe Capital also participated in the series-C.

The fresh capital will help the business accelerate the development of its antibody drug pipeline. Hifibio expects to see multiple drug candidates advance to the clinical trial phase.

The company's previous round of funding was a $38m series-B led by Sequoia China and Lyfe Capital in Q2 2018.

Company
Founded in 2013, Hifibio is a biotherapeutics company with a pipeline including antibody drugs treating cancer and autoimmune disorders. Since its latest funding round in Q2 2018, the company has developed partnerships with other biopharmas, and completed an acquisition and a joint venture. Based in Paris, Hifibio also has a presence in the US and China.

People
Hifibio Therapeutics – Liang Schweizer (president, CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• France
• Healthcare
• France
• Venture